The Role of Oral Glutathione on Growth Parameters in Children With Cystic Fibrosis
- Registration Number
- NCT03020719
- Lead Sponsor
- University of Minnesota
- Brief Summary
The purpose of this randomized, placebo-controlled (Phase II) study will be to further evaluate the effects of oral glutathione on growth in children with CF.
- Detailed Description
a prospective, multi-center, randomized, placebocontrolled, double-blind, Phase II clinical trial. Approximately sixty pancreatic insufficient (PI) subjects with CF who are ≥ 2 and \< 11 years of age, will be enrolled to receive either L-Glutathione Reduced (GSH) or placebo given orally (tid) for 24 weeks. Each subject will be seen for four study visits: Visit 1 (Screening), Visit 2 (Baseline/Randomization, Day 0), Visit 3 (Week 12) and Visit 4 (Week 24). At Visit 2, subjects will be randomized to receive either active treatment or placebo. Visit 1 and 2 may be combined if subject meets eligibility requirements and a fecal specimen is collected prior to dosing. Safety and clinical outcomes will be assessed throughout the study. Assessment of inflammatory and other bio-markers in blood and fecal specimens will be performed at Visits 2 and 4
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 60
- Male or female ≥ 2 and < 11 years of age at Visit 1
- Documentation of a CF diagnosis as evidenced by the following criteria: Sweat chloride ≥ 60 mEq/L by quantitative pilocarpine iontophoresis test (QPIT) AND Two well-characterized mutations in the cystic fibrosis transmembrane conductive regulator (CFTR) gene
- Weight-for-age between the 10th and 50th percentiles at Screening (Visit 1) (using the Center for Disease Control (CDC) reference equations)
- Current chronic use, greater than 8 weeks before Day 0, of pancreatic enzyme replacement therapy (PERT) for management of pancreatic insufficiency
- Written informed consent (and assent when applicable) obtained from subject or subject's legal representative and ability to comply with the requirements of the study
- Clinically stable with no significant changes in health status within 2 weeks prior to Day 0
-
- Intestinal obstruction or gastrointestinal surgery within the 6 months prior to Day 0 2. History of diabetes, Crohn's disease, celiac disease, or bowel resection 3. Use of either oral or inhaled GSH or N-acetyl cysteine within the 4 months prior to Screening (Visit 1) 4. Known hypersensitivity to oral glutathione or lactose 5. Initiation of any new chronic therapy (e.g., ibuprofen, hypertonic saline, azithromycin, Pulmozyme, Cayston TOBI Kalydeco,Orkambi, Proton Pump Inhibitor, Histamine H-2 Blocker [PPI/H2-blocker], Miralax® , PERT, dietary supplementation, probiotics) within the 4 weeks prior to Day 0 6. Changes in the amount of proprietary dietary supplement formulas (e.g., Scandishakes, Boost, Pediasure, or homemade formula) given (oral or gastrostomy tube) within the 4 weeks prior to Day 0 7. Use of antibiotics (oral, IV, or inhaled) for acute symptoms within the 2 weeks prior to Day 0 8. Use of oral steroids within the 4 weeks prior to Day 0 9. Active treatment for nontuberculous mycobacteria (NTM) at Day 0 10. Active treatment for allergic bronchopulmonary aspergillosis (ABPA) at Day 0 11. Administration of any investigational drug within the 30 days prior to Day 0 12. Sibling who received study drug as part of this study 13. Presence of a condition or abnormality that in the opinion of the investigator would compromise the safety of the patient or the quality of the data
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Oral Glutathione Oral Glutathione Oral Glutathione oral powder at 65mg/kg/day Placebo Placebo Placebo oral powder at 65mg/kg/day
- Primary Outcome Measures
Name Time Method Change in Weight-for-age Z-score Baseline to 24 weeks Difference between the oral glutathione and placebo groups in the 24-week change from baseline in weight-for-age Z-score. Weight-for-age Z-scores are derived from the 2000 Centers for Disease Control and Prevention growth charts for U.S. children. The reference population in these growth charts is children surveyed by the National Center for Health Statistics from 1963-65 to 1988-94. The Z-score indicates the number of standard deviations away from the mean of the reference population. A negative Z-score indicates values lower than the mean while a positive Z-score indicates values higher than the mean.
- Secondary Outcome Measures
Name Time Method Change in Height-for-age Z-score Baseline to 24 weeks Difference between the oral glutathione and placebo groups in the 24-week change from baseline in height-for-age Z-score. Height-for-age Z-scores are derived from the 2000 Centers for Disease Control and Prevention growth charts for U.S. children. The reference population in these growth charts is children surveyed by the National Center for Health Statistics from 1963-65 to 1988-94. The Z-score indicates the number of standard deviations away from the mean of the reference population. A negative Z-score indicates values lower than the mean while a positive Z-score indicates values higher than the mean.
Change in BMI-for-age Z-score Baseline to 24 weeks Difference between the oral glutathione and placebo groups in the 24-week change from baseline in BMI-for-age Z-score. BMI-for-age Z-scores are derived from the 2000 Centers for Disease Control and Prevention growth charts for U.S. children. The reference population in these growth charts is children surveyed by the National Center for Health Statistics from 1963-65 to 1988-94. The Z-score indicates the number of standard deviations away from the mean of the reference population. A negative Z-score indicates values lower than the mean while a positive Z-score indicates values higher than the mean.
Change in Fecal Calprotectin Baseline to 24 weeks Difference between the oral glutathione and placebo groups in the 24-week change from baseline in fecal calprotectin.
Change in High-sensitivity C-reactive Protein (Hs-CRP) Baseline to 24 weeks Difference between the oral glutathione and placebo groups in the 24-week change from baseline in hs-CRP.
Adverse Events (AEs) and Serious Adverse Events (SAEs) Baseline to 24 weeks The number and percentage of participants with at least one event over the 24 week follow-up period.
Rate of Adverse Events (AEs) and Serious Adverse Events (SAEs) Baseline to 24 weeks Rate is defined as the number of events per participant follow-up month.
Trial Locations
- Locations (18)
The University of Vermont Inc.
🇺🇸Burlington, Vermont, United States
Nemours Childrens Clinic
🇺🇸Jacksonville, Florida, United States
Connecticut Childrens Medical Center
🇺🇸Hartford, Connecticut, United States
Riley Children's Hospital
🇺🇸Indianapolis, Indiana, United States
The Childrens Mercy Hospital
🇺🇸Kansas City, Missouri, United States
University of Minnesota Medical Center
🇺🇸Minneapolis, Minnesota, United States
UT Southwestern Medical Center
🇺🇸Dallas, Texas, United States
Women and Childrens Hospital of Buffalo
🇺🇸Buffalo, New York, United States
Oregon Health & Science University
🇺🇸Portland, Oregon, United States
Childrens Hospital of New York/Columbia University Medical Center
🇺🇸New York, New York, United States
Baylor College of Medicine
🇺🇸Houston, Texas, United States
University of Virginia Health System
🇺🇸Charlottesville, Virginia, United States
Childrens Hospital Colorado
🇺🇸Aurora, Colorado, United States
Nemours Children's Clinic
🇺🇸Pensacola, Florida, United States
Emory University Hospital
🇺🇸Atlanta, Georgia, United States
Childrens Hospital of Michigan
🇺🇸Detroit, Michigan, United States
Helen DeVos Women and Childrens Center
🇺🇸Grand Rapids, Michigan, United States
Childrens Hospital of Milwaukee
🇺🇸Milwaukee, Wisconsin, United States